6505--6505 - VISN 2 DOWNSTATE GENERAL RADIOPHARMACEUTICALS
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), Network Contracting Office 2, has awarded a contract for General Radiopharmaceuticals to NUCLEAR DIAGNOSTIC PRODUCTS, INC. The award, valued at $959,170.05, was made on February 24, 2026. This contract ensures the continued provision of essential radiopharmaceuticals for VA Medical Centers in VISN 2 (New York and New Jersey).
Scope of Work
The awarded contract covers the daily delivery of unit and bulk dose radiopharmaceuticals, radiopharmaceuticals for Quality Control (QC) procedures, and related supplies. Services include labor, supervision, and transportation to specific VA Medical Centers, including Manhattan, Brooklyn, Castle Point, East Orange, Northport, and Bronx. The contractor is also responsible for maintaining an adequate supply of products and providing miscellaneous supplies and services such as diagnostic and therapeutic radiopharmaceutical products, sealed radioactive sources for QC, and RSO safety audits.
Contract & Timeline
- Awardee: NUCLEAR DIAGNOSTIC PRODUCTS, INC.
- Award Number: 36C24226D0037
- Award Amount: $959,170.05
- Award Date: February 24, 2026
- Product Service Code (PSC): 6505 (Drugs And Biologicals)
- NAICS Code: 325412 (Pharmaceutical Preparation Manufacturing)
- Set-Aside: Not specified in the award notice.
Additional Context
Prior to this award, the VA had issued a Notice of Intent to Award a Sole Source Contract to Nuclear Diagnostic Products, Inc. for a short-term period (February 22, 2026, through December 31, 2026) to bridge services while a multi-year contract was developed. This award appears to be the result of that process, ensuring uninterrupted nuclear medicine services for veterans.